Paul A Watkins
Overview
Explore the profile of Paul A Watkins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
1790
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ye X, Li Y, Gonzalez-Lamuno D, Pei Z, Moser A, Smith K, et al.
Cells
. 2024 Oct;
13(20.
PMID: 39451204
"Bubblegum" acyl-CoA synthetase (ACSBG1) is a pivotal player in lipid metabolism during mouse brain development, facilitating the activation of long-chain fatty acids (LCFA) and their incorporation into lipid species that...
2.
Ye X, Li Y, Gonzalez-Lamuno D, Pei Z, Moser A, Smith K, et al.
bioRxiv
. 2024 Jul;
PMID: 38948805
The "bubblegum" acyl-CoA synthetase (ACSBG1) is a pivotal player in lipid metabolism during the development of the mouse brain, facilitating the activation of long-chain fatty acids (LCFAs) and their integration...
3.
Kolar E, Shi X, Clay E, Liu Y, Xia S, Zhang C, et al.
bioRxiv
. 2023 Oct;
PMID: 37786718
Knockout (KO) of the fatty acid-activation enzyme very long-chain acyl-CoA synthetase 3 (ACSVL3; SLC27A3) in U87MG glioblastoma cells reduced their malignant growth properties both in vitro and in xenografts. These...
4.
Yang H, Shi X, Kolar E, Clay E, Xia S, Pei Z, et al.
bioRxiv
. 2023 May;
PMID: 37205435
Decreasing the expression of very long-chain acyl-CoA synthetase 3 (ACSVL3) in U87MG glioblastoma cells by either RNA interference or genomic knockout (KO) significantly decreased their growth rate in culture, as...
5.
Terluk M, Tieu J, Sahasrabudhe S, Moser A, Watkins P, Raymond G, et al.
Neurotherapeutics
. 2022 Apr;
19(3):1007-1017.
PMID: 35378685
Adrenoleukodystrophy (ALD) is an X-linked inherited peroxisomal disorder due to mutations in the ALD protein and characterized by accumulation of very long-chain fatty acids (VLCFA), specifically hexacosanoic acid (C26:0). This...
6.
Kolar E, Shi X, Clay E, Moser A, Lal B, Nirujogi R, et al.
Med Res Arch
. 2021 Aug;
9(5).
PMID: 34395855
Gliomas are the largest category of primary malignant brain tumors in adults, and glioblastomas account for nearly half of malignant gliomas. Glioblastomas are notoriously aggressive and drug-resistant, with a very...
7.
Moser A, Liu Y, Shi X, Schrifl U, Hiebler S, Fatemi A, et al.
J Cell Biochem
. 2021 May;
122(10):1337-1349.
PMID: 34056752
X-linked adrenoleukodystrophy (XALD) is a genetic neurologic disorder with multiple phenotypic presentations and limited therapeutic options. The childhood cerebral phenotype (CCALD), a fatal demyelinating disorder affecting about 35% of patients,...
8.
Tan S, Little H, Sarver D, Watkins P, Wong G
FEBS Lett
. 2020 Aug;
594(19):3227-3239.
PMID: 32749667
C1q/TNF-related protein 12 (CTRP12) is an antidiabetic adipokine whose circulating levels are reduced in obesity and diabetes. Although partial and complete loss-of-function mouse models suggest a role for CTRP12 in...
9.
Geller G, Watkins P
AMA J Ethics
. 2018 Oct;
20(10):E948-959.
PMID: 30346923
Context: Negative bias toward patients with obesity is an ethical challenge in patient care. Several interventions to mitigate medical students' negative weight bias have been tried but none with an...
10.
Turk B, Nemeth C, Marx J, Tiffany C, Jones R, Theisen B, et al.
Ann Neurol
. 2018 Aug;
84(3):452-462.
PMID: 30069915
Objective: X-linked adrenoleukodystrophy (ALD) is a neurodegenerative disorder due to mutations in the peroxisomal very long-chain fatty acyl-CoA transporter, ABCD1, with limited therapeutic options. ALD may manifest in a slowly...